WELCOME to Neurodyn

Neurodyn Inc. utilizes a portfolio approach to identify, validate and develop bioactives for neuroprotection and the early treatment of neurological diseases.  Neurodyn finds bioactive compounds within historically-proven natural treatments, de-risks and protects these compounds, reaches a significant value-inflection point, and partners early and aggressively in order to provide early returns. Neurodyn will out-license or sell validated therapeutic candidates to pharmaceutical and consumer health players, as well as explore faster alternatives to traditional drug development, such as the US FDA Medical Food designation.

Neurodyn has built a strong development capacity based on:

1) International partners with demonstrated historical knowledge of natural compounds,
2) in-house medicinal chemistry capability, and
3) proprietary animal models of neurological disease.

This combination of expertise provides Neurodyn with a unique insight into the discovery, validation and development of new bioactive compounds for the treatment of neurological diseases.

NeuroQuest Inc. (neuroquest.ca), a wholly-owned subsidiary, offers synthesis, medicinal chemistry and in vitro screening programs for the molecular modification of promising bioactive compounds. more

CNS CRO (cnscro.com), a second wholly-owned contract research subsidiary of Neurodyn, offers specialty and proprietary animal models for ALS, Parkinson's disease (PD), Alzheimer's disease (AD), epilepsy, schizophrenia, stroke and cognitive function testing. more

TECHNOLOGY Overview

The company currently has a robust suite of drug candidates from its BioActives Discovery Engine™ which are ready for out-license (with additional technologies under evaluation):

 

ND1208

NeuroPro is a neuroprotection product for early stage Parkinson’s disease, which has demonstrated compelling in vivo pre-clinical efficacy in acute (MPTP based) animal models as well as Neurodyn’s proprietary chronic progressive model of Parkinson's disease. NeuroPro is available for sale in Canada and a Canadian observational study is being conducted in early 2013.  A Medical Food version of NeuroPro is expected to launch in the USA in 2014... more

ND602

ND602 is a novel therapeutic demonstrating in vivo pre-clinical efficacy in ALS, PD, Alzheimer's disease and Spinal Muscular Atrophy. The company is in its third year of collaboration (late stage pre-clinical evaluation) with the Michael J. Fox Foundation... more

NQ1123

NQ1123 is a lead drug candidate within a class of compounds showing rare first-in-class state-dependent neuromodulation and dual mechanisms of action for Nav and TRP channels.  These new chemical entities are based on in vivo and human clinic validated natural bioactives.  Lead optimization over the coming year with provide the basis for an IND filing for a topical orphan status nerve pain condition...  more